Protocol Ledger

NCT06837233 · Phase II · COMPLETED

A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis

Interventional Phase II clinical trial protocol NCT06837233 sponsored by Prime Gene Therapeutics Co in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-12 Enrollment: 179 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06837233
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)179 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06837233
Protocol FieldVerified Registry Value
NCT IdentifierNCT06837233
Consolidated Lead SponsorPrime Gene Therapeutics Co
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment179 participants (ACTUAL)
Registered Start Date2025-03-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06837233
Hospital Research SiteLocationSite Profile
Beijing Tongren Hospital, Capital Medical UniversityBeijing, ChinaOpen Hospital Dossier ->
Shengjing hospital of China medical universityShenyang, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI